Peng Xue Selected Research

Biomarkers (Surrogate Marker)

1/2022	Metabolomics based plasma biomarkers for diagnosis of oral squamous cell carcinoma and oral erosive lichen planus.
10/2021	Prognostic and immunological value of LTB4R in pan-cancer.
10/2021	Fusion of 3D lung CT and serum biomarkers for diagnosis of multiple pathological types on pulmonary nodules.
1/2021	Human Saliva Metabolome for Oral Lichen Planus Biomarker Identification.
1/2021	Metabolomics and Transcriptomics Analysis on Metabolic Characteristics of Oral Lichen Planus.
1/2021	Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis.
1/2020	Potential Metabolic Biomarkers for Early Detection of Oral Lichen Planus, a Precancerous Lesion.
1/2020	Metabolomic Insights Into the Synergistic Effect of Biapenem in Combination With Xuebijing Injection Against Sepsis.
1/2017	Serum glycopattern and Maackia amurensis lectin-II binding glycoproteins in autism spectrum disorder.
3/2016	[Metabolomics analysis on serum biomarkers timing characteristics of type 2 diabetic rats intervened by exercise].

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peng Xue Research Topics

Disease

101	Neoplasms (Cancer) 10/2022 - 02/2009
13	Inflammation (Inflammations) 10/2022 - 04/2011
10	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2014
9	Type 2 Diabetes Mellitus (MODY) 01/2020 - 04/2011
8	Pain (Aches) 02/2022 - 04/2013
8	Breast Neoplasms (Breast Cancer) 01/2022 - 03/2012
6	Hypoxia (Hypoxemia) 01/2022 - 01/2012
6	Pancreatic Neoplasms (Pancreatic Cancer) 07/2021 - 04/2014
5	Hyperthermia 01/2022 - 01/2018
5	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2003
5	Insulin Resistance 01/2016 - 04/2011
4	Prostatic Neoplasms (Prostate Cancer) 11/2021 - 08/2015
4	Infections 10/2021 - 01/2009
4	Osteoporosis 01/2021 - 12/2016
4	Periodontitis 01/2021 - 05/2014
4	Urinary Bladder Neoplasms (Bladder Cancer) 10/2017 - 01/2015
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2016 - 08/2012
3	Colorectal Neoplasms (Colorectal Cancer) 05/2022 - 01/2012
3	Oral Lichen Planus 01/2021 - 01/2020
3	Adenocarcinoma of Lung 01/2020 - 01/2003
3	Hepatocellular Carcinoma (Hepatoma) 09/2019 - 01/2003
3	Skin Neoplasms (Skin Cancer) 01/2013 - 01/2011
2	Necrosis 05/2022 - 10/2018
2	Muscular Atrophy (Muscle Atrophy) 02/2022 - 01/2021
2	Atrophy 02/2022 - 01/2021
2	Neuralgia (Stump Neuralgia) 02/2022 - 01/2022
2	Shock 01/2022 - 01/2020
2	Starvation 01/2022 - 01/2020
2	Adenocarcinoma 10/2021 - 08/2017
2	Stomach Neoplasms (Stomach Cancer) 07/2021 - 08/2017
2	Bone Resorption 01/2021 - 10/2020

Drug/Important Bio-Agent (IBA)

32	Pharmaceutical PreparationsIBA 07/2022 - 11/2013
18	ProdrugsIBA 01/2022 - 11/2016
18	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2003
14	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2008
12	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2015
10	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2021 - 10/2018
10	MicellesIBA 01/2020 - 09/2017
9	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 04/2011
8	Biological ProductsIBA 02/2022 - 10/2009
8	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 01/2018
6	Therapeutic UsesIBA 01/2021 - 01/2018
6	Oxygen (Dioxygen)IBA 01/2021 - 11/2019
6	ferric ferrocyanide (Prussian blue)FDA Link 03/2019 - 01/2015
6	ArsenicIBA 02/2013 - 01/2011
5	AcidsIBA 10/2021 - 11/2017
5	phytochlorinIBA 01/2020 - 10/2018
5	Insulin (Novolin)FDA Link 01/2020 - 04/2011
4	HydrogelsIBA 03/2022 - 12/2018
4	DisulfidesIBA 01/2022 - 01/2016
4	MicroRNAs (MicroRNA)IBA 01/2022 - 02/2015
4	Glutathione (Reduced Glutathione)IBA 01/2022 - 01/2016
4	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 04/2017
4	PolymersIBA 09/2021 - 09/2017
4	CamptothecinIBA 02/2021 - 11/2017
4	Photosensitizing Agents (Photosensitizers)IBA 01/2021 - 01/2019
4	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2020 - 02/2017
4	AntigensIBA 04/2014 - 03/2013
3	polyethylene glycol polyethyleneimine nanogelIBA 06/2022 - 02/2021
3	Amino Acids FDA Link 03/2022 - 05/2014
3	Fibroins (Fibroin)IBA 01/2022 - 01/2019
3	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2021 - 01/2018
3	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2021
3	Liraglutide FDA Link 10/2020 - 10/2019
3	Sulfides (Thioethers)IBA 06/2020 - 01/2019
3	CopperIBA 06/2020 - 01/2019
3	CyclodextrinsIBA 11/2019 - 08/2018
3	Glycoproteins (Glycoprotein)IBA 01/2019 - 01/2017
3	IsotopesIBA 02/2017 - 05/2014
3	Carcinoembryonic AntigenIBA 04/2014 - 02/2014
3	CarbohydratesIBA 04/2014 - 02/2014
3	LipidsIBA 03/2013 - 08/2012
2	Biocompatible Materials (Biomaterials)IBA 10/2022 - 01/2020
2	SaponinsIBA 05/2022 - 02/2019
2	Metal-Organic FrameworksIBA 01/2022 - 02/2015
2	Mannose (D-Mannose)IBA 01/2022 - 01/2022
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2022 - 01/2021
2	CytokinesIBA 12/2021 - 10/2017
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2021 - 01/2019
2	Dinoprostone (PGE2)FDA Link 08/2021 - 01/2021
2	Transcription Factors (Transcription Factor)IBA 06/2021 - 03/2010
2	cinobufotalinIBA 01/2021 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2011
2	SolutionsIBA 01/2021 - 02/2015
2	zirconium oxide (zirconia)IBA 01/2021 - 11/2019
2	Humic SubstancesIBA 01/2020 - 12/2018
2	bismuth selenideIBA 01/2020 - 07/2019
2	AndrogensIBA 01/2020 - 08/2015

Therapy/Procedure

63	Therapeutics 01/2022 - 01/2015
27	Drug Therapy (Chemotherapy) 05/2022 - 01/2012
13	Lasers (Laser) 01/2022 - 03/2012
12	Precision Medicine 01/2021 - 11/2017
10	Photochemotherapy (Photodynamic Therapy) 01/2021 - 10/2018
7	Photothermal Therapy 01/2022 - 01/2015
5	Immunotherapy 10/2022 - 01/2020
3	Aftercare (After-Treatment) 02/2022 - 04/2019
3	Induced Hyperthermia (Thermotherapy) 11/2020 - 01/2020
2	Phototherapy (Light Therapy) 01/2022 - 10/2019
2	Radiotherapy 01/2022 - 01/2020
2	Castration 01/2020 - 08/2015